JP2013500711A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500711A5
JP2013500711A5 JP2012522191A JP2012522191A JP2013500711A5 JP 2013500711 A5 JP2013500711 A5 JP 2013500711A5 JP 2012522191 A JP2012522191 A JP 2012522191A JP 2012522191 A JP2012522191 A JP 2012522191A JP 2013500711 A5 JP2013500711 A5 JP 2013500711A5
Authority
JP
Japan
Prior art keywords
protein
adamts13
buffer
adamts13 protein
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012522191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500711A (ja
JP5907869B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/061192 external-priority patent/WO2011012726A2/en
Publication of JP2013500711A publication Critical patent/JP2013500711A/ja
Publication of JP2013500711A5 publication Critical patent/JP2013500711A5/ja
Application granted granted Critical
Publication of JP5907869B2 publication Critical patent/JP5907869B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012522191A 2009-07-31 2010-08-02 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物 Active JP5907869B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
US61/230,308 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105808A Division JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Publications (3)

Publication Number Publication Date
JP2013500711A JP2013500711A (ja) 2013-01-10
JP2013500711A5 true JP2013500711A5 (enExample) 2013-09-12
JP5907869B2 JP5907869B2 (ja) 2016-04-26

Family

ID=42588355

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012522191A Active JP5907869B2 (ja) 2009-07-31 2010-08-02 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2015105808A Active JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2016194640A Withdrawn JP2016222724A (ja) 2009-07-31 2016-09-30 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2018188301A Withdrawn JP2018203781A (ja) 2009-07-31 2018-10-03 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2020174837A Pending JP2021004265A (ja) 2009-07-31 2020-10-16 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2022150048A Pending JP2022171925A (ja) 2009-07-31 2022-09-21 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015105808A Active JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2016194640A Withdrawn JP2016222724A (ja) 2009-07-31 2016-09-30 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2018188301A Withdrawn JP2018203781A (ja) 2009-07-31 2018-10-03 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2020174837A Pending JP2021004265A (ja) 2009-07-31 2020-10-16 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2022150048A Pending JP2022171925A (ja) 2009-07-31 2022-09-21 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Country Status (22)

Country Link
US (3) US8945895B2 (enExample)
EP (3) EP2459715B1 (enExample)
JP (6) JP5907869B2 (enExample)
KR (7) KR101769634B1 (enExample)
CN (3) CN107988192A (enExample)
AU (1) AU2010277491B2 (enExample)
CA (2) CA2916508A1 (enExample)
CO (1) CO6612194A2 (enExample)
DK (1) DK2459715T3 (enExample)
EA (3) EA034292B1 (enExample)
ES (3) ES3039686T3 (enExample)
HR (1) HRP20192303T1 (enExample)
HU (1) HUE046909T2 (enExample)
IN (1) IN2012DN00907A (enExample)
LT (1) LT2459715T (enExample)
MX (2) MX2012001263A (enExample)
NZ (2) NZ620988A (enExample)
PL (2) PL2459715T3 (enExample)
PT (1) PT2459715T (enExample)
SG (2) SG178175A1 (enExample)
SI (1) SI2459715T1 (enExample)
WO (1) WO2011012726A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170001720A (ko) 2007-03-14 2017-01-04 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
MY195362A (en) * 2012-06-21 2023-01-16 Baxalta Inc Virus Filtration of Cell Culture Media
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
CN119979504A (zh) * 2013-01-09 2025-05-13 武田药品工业株式会社 含用于纯化芳基硫酸酯酶a的方法
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
NZ750146A (en) 2016-08-04 2025-10-31 Takeda Pharmaceuticals Co Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3773969A1 (en) * 2018-04-03 2021-02-17 Merck Patent GmbH Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
AU2020253381A1 (en) * 2019-04-03 2021-12-02 Genzyme Corporation Continuous production of recombinant proteins
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
EP4490179A1 (en) 2022-03-07 2025-01-15 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
WO2025224621A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69329108T2 (de) 1992-03-02 2001-03-22 Bioeng, Inc. Verfahren zur inaktivierung von viren
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4707231B2 (ja) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
JPWO2002031163A1 (ja) * 2000-10-11 2004-02-19 財団法人かずさディー・エヌ・エー研究所 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
US20060110407A1 (en) * 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
WO2003059935A2 (en) 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
DE602004029058D1 (de) 2003-07-09 2010-10-21 Shinonogi & Co Ltd Inducer von atopischer dermatitis
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US20080138790A1 (en) * 2004-04-13 2008-06-12 Winslow Robert M Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses
PL1765866T3 (pl) 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
WO2006072579A1 (en) * 2005-01-05 2006-07-13 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
AU2006257073B2 (en) 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
EP1968999A2 (en) * 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
ES2386574T3 (es) 2006-02-16 2012-08-23 Mitsubishi Chemical Medience Corporation Procedimiento de detección de afección en paciente con alteración de la consciencia
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
JP5254973B2 (ja) 2007-06-22 2013-08-07 一般財団法人化学及血清療法研究所 新規ａｄａｍｔｓ−１３改変体
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Similar Documents

Publication Publication Date Title
JP2013500711A5 (enExample)
HRP20192303T1 (hr) Postupak za pročišćavanje rekombinantnog adamts13 i drugih proteina i njihovih pripravaka
RU2015141849A (ru) Способ очистки фактора свертывания крови viii
JP2011510303A5 (enExample)
EP0443724B1 (en) Viral-safe purified human thrombin
JP6720288B2 (ja) ウイルス用無菌精製プロセス
JP2011525523A5 (enExample)
JPS61275210A (ja) ウイルス及び発熱原不活性化剤を用いる固相に吸着させた生物医学的生成物及び製薬生成物の処理法
EP3133157A1 (en) A process for purifying vitamin k dependent proteins
JPS5944320A (ja) Ｃ１不活性化剤の調製方法
CN105566489B (zh) 一种制备不同铁饱和度乳铁蛋白的方法
CN102234332B (zh) 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
CN103534264B (zh) 血栓形成试剂减少的免疫球蛋白及其制备
JP2001524953A (ja) 免疫寛容プロトロンビン複合体の調製
ES2743711T3 (es) Un proceso para la reducción y/o retirada de FXI y FXIa de soluciones que contienen fichos factores de coagulación
JP2014518508A5 (enExample)
US20130164821A1 (en) Method for separating viruses from a contaminant-containing liquid
JP5137491B2 (ja) 水酸化アルミニウム吸着体の吸着性及び／又は溶出性の改変方法
RU2332247C1 (ru) Способ очистки иммуноглобулина (варианты)
JP2009039038A (ja) 被分離物質の分離方法及び精製方法
CN1798573A (zh) 白蛋白溶液及其制备方法
AU739845B2 (en) A method for inactivating pathogens, in particular viruses, in a biological material
JP2009042074A (ja) 吸着担体及び吸着担体の製造方法
JP2007238479A (ja) ハイドロキシアパタイトに吸着された有機物の溶出方法及び該溶出方法を用いた有機物の精製方法
RU2559576C1 (ru) Способ получения вирусбезопасного полного протромбинового комплекса